FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022169488> ?p ?o ?g. }

• W2022169488 endingPage "495" @default.
• W2022169488 startingPage "489" @default.
• W2022169488 abstract "Goals and Background The multikinase inhibitor sorafenib provides survival benefit for patients with advanced hepatocellular carcinoma (HCC) and liver cirrhosis (LCI) Child-Pugh A. We report our experiences with sorafenib in advanced HCC, particularly in patients with LCI Child-Pugh B/C, where only limited data are available in regard to safety and efficacy of sorafenib. Methods Thirty-four patients with advanced HCC were treated with sorafenib regardless of liver function and prior anticancer therapy. Adverse events (AEs) were graded using Common Toxicity Criteria version 3.0, tumor response was assessed according to Response Evaluation Criteria in Solid Tumors. Results Fifteen patients presented without LCI or with LCI Child-Pugh A, 15/4 patients had LCI Child-Pugh B/C. Barcelona Clinic Liver Cancer stage was B/C/D in 4/22/8 patients. During treatment period (median 2.2 mo), therapy was discontinued in 61.8% of patients due to tumor progression (32.3%), death (17.6%), AEs (8.8%), or noncompliance (2.9%). Most common grade 3/4 AEs included liver dysfunction (23.5%), diarrhea (14.7%), increased lipase (8.8%), fatigue (8.8%), and hand-foot skin reaction (5.9%). Worsening liver dysfunction/failure was more frequent (P=0.036) in patients with LCI Child-Pugh B/C compared with patients with maintained liver function (no LCI/LCI Child-Pugh A). Median overall survival was 7.2 months for patients with maintained liver function versus 3.3/3.4 months for patients with LCI Child-Pugh B/C. Conclusions These data do not support the use of sorafenib in patients with LCI Child-Pugh C, and patients with LCI Child-Pugh B should be treated with caution until larger trials provide more safety data and a clinically relevant survival benefit under sorafenib therapy." @default.
• W2022169488 created "2016-06-24" @default.
• W2022169488 creator A5001626414 @default.
• W2022169488 creator A5002788152 @default.
• W2022169488 creator A5004228804 @default.
• W2022169488 creator A5025956524 @default.
• W2022169488 creator A5038203864 @default.
• W2022169488 creator A5056118702 @default.
• W2022169488 creator A5059354270 @default.
• W2022169488 creator A5068563424 @default.
• W2022169488 creator A5080906069 @default.
• W2022169488 creator A5083168604 @default.
• W2022169488 creator A5085131013 @default.
• W2022169488 creator A5089643041 @default.
• W2022169488 date "2009-05-01" @default.
• W2022169488 modified "2023-10-14" @default.
• W2022169488 title "Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis" @default.
• W2022169488 cites W1968626722 @default.
• W2022169488 cites W1971837077 @default.
• W2022169488 cites W1993919875 @default.
• W2022169488 cites W1999966467 @default.
• W2022169488 cites W2020215421 @default.
• W2022169488 cites W2020830322 @default.
• W2022169488 cites W2021760512 @default.
• W2022169488 cites W2034483448 @default.
• W2022169488 cites W2055590215 @default.
• W2022169488 cites W2070396671 @default.
• W2022169488 cites W2116177733 @default.
• W2022169488 cites W2133559579 @default.
• W2022169488 cites W2138610774 @default.
• W2022169488 cites W2139248078 @default.
• W2022169488 cites W2140765540 @default.
• W2022169488 cites W2147172608 @default.
• W2022169488 cites W2156871508 @default.
• W2022169488 cites W2163486683 @default.
• W2022169488 cites W2166973314 @default.
• W2022169488 cites W4243625103 @default.
• W2022169488 doi "https://doi.org/10.1097/mcg.0b013e31818ddfc6" @default.
• W2022169488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19247201" @default.
• W2022169488 hasPublicationYear "2009" @default.
• W2022169488 type Work @default.
• W2022169488 sameAs 2022169488 @default.
• W2022169488 citedByCount "142" @default.
• W2022169488 countsByYear W20221694882012 @default.
• W2022169488 countsByYear W20221694882013 @default.
• W2022169488 countsByYear W20221694882014 @default.
• W2022169488 countsByYear W20221694882015 @default.
• W2022169488 countsByYear W20221694882016 @default.
• W2022169488 countsByYear W20221694882017 @default.
• W2022169488 countsByYear W20221694882018 @default.
• W2022169488 countsByYear W20221694882019 @default.
• W2022169488 countsByYear W20221694882020 @default.
• W2022169488 countsByYear W20221694882021 @default.
• W2022169488 countsByYear W20221694882022 @default.
• W2022169488 countsByYear W20221694882023 @default.
• W2022169488 crossrefType "journal-article" @default.
• W2022169488 hasAuthorship W2022169488A5001626414 @default.
• W2022169488 hasAuthorship W2022169488A5002788152 @default.
• W2022169488 hasAuthorship W2022169488A5004228804 @default.
• W2022169488 hasAuthorship W2022169488A5025956524 @default.
• W2022169488 hasAuthorship W2022169488A5038203864 @default.
• W2022169488 hasAuthorship W2022169488A5056118702 @default.
• W2022169488 hasAuthorship W2022169488A5059354270 @default.
• W2022169488 hasAuthorship W2022169488A5068563424 @default.
• W2022169488 hasAuthorship W2022169488A5080906069 @default.
• W2022169488 hasAuthorship W2022169488A5083168604 @default.
• W2022169488 hasAuthorship W2022169488A5085131013 @default.
• W2022169488 hasAuthorship W2022169488A5089643041 @default.
• W2022169488 hasConcept C126322002 @default.
• W2022169488 hasConcept C143998085 @default.
• W2022169488 hasConcept C197934379 @default.
• W2022169488 hasConcept C2776231280 @default.
• W2022169488 hasConcept C2777214474 @default.
• W2022169488 hasConcept C2778019345 @default.
• W2022169488 hasConcept C2778695046 @default.
• W2022169488 hasConcept C2779384505 @default.
• W2022169488 hasConcept C2779984678 @default.
• W2022169488 hasConcept C29730261 @default.
• W2022169488 hasConcept C2992208098 @default.
• W2022169488 hasConcept C31760486 @default.
• W2022169488 hasConcept C512861765 @default.
• W2022169488 hasConcept C71924100 @default.
• W2022169488 hasConcept C90924648 @default.
• W2022169488 hasConceptScore W2022169488C126322002 @default.
• W2022169488 hasConceptScore W2022169488C143998085 @default.
• W2022169488 hasConceptScore W2022169488C197934379 @default.
• W2022169488 hasConceptScore W2022169488C2776231280 @default.
• W2022169488 hasConceptScore W2022169488C2777214474 @default.
• W2022169488 hasConceptScore W2022169488C2778019345 @default.
• W2022169488 hasConceptScore W2022169488C2778695046 @default.
• W2022169488 hasConceptScore W2022169488C2779384505 @default.
• W2022169488 hasConceptScore W2022169488C2779984678 @default.
• W2022169488 hasConceptScore W2022169488C29730261 @default.
• W2022169488 hasConceptScore W2022169488C2992208098 @default.
• W2022169488 hasConceptScore W2022169488C31760486 @default.
• W2022169488 hasConceptScore W2022169488C512861765 @default.
• W2022169488 hasConceptScore W2022169488C71924100 @default.
• W2022169488 hasConceptScore W2022169488C90924648 @default.

• next